Allakos is a clinical-stage biotechnology company that develops therapeutic antibodies for the treatment of various allergic and inflammatory diseases. The company's lead product candidate, AK002, is being developed for the treatment of eosinophilic gastritis and eosinophilic esophagitis. Allakos was founded in 2012 by Nenad Tomasevic and is headquartered in Redwood City, California.